Abstract
Abbreviations: MLST, multi-locus sequence typing; OMP, outer-membrane protein
Part of this work was done at the Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.
The GenBank/EMBL/DDBJ accession numbers for the vuuA sequences reported in this paper are DQ973529, DQ973530 and DQ980539; for the wcvI sequences, DQ980540 and DQ980541; for the wza sequences, DQ980542 and DQ980543; and for the ompU sequences, DQ980544, DQ980545 and DQ980546.
Several molecular techniques have been applied in an attempt to better characterize this emerging pathogen (biotype 3). By pulsed field gel electrophoresis (PFGE) the strains were non-typable (Bisharat et al., 1999). PCR-RFLP (restriction fragment length polymorphism) of the cytotoxin-haemolysin gene showed that all biotype 3 strains were indistinguishable and distinct from biotypes 1 and 2 (Bisharat et al., 1999). Similar results were obtained using multi-locus enzyme electrophoresis (Gutacker et al., 2003). Recent work, based on multi-locus sequence typing (MLST) data revealed that biotype 3 is a recombinant clone that evolved by the hybridization between two populations (Bisharat et al., 2005). The analysis also showed that all the strains belonging to this clone were genetically uniform among all 10 housekeeping genes analysed.
The fundamental concept behind MLST is to analyse DNA sequence diversity within housekeeping genes encoding enzymes involved in intermediary metabolism, which are not subject to any unusual selective forces, and diversify slowly by the random accumulation of neutral mutations, and therefore better reflect the genetic population structure of the species (Maiden et al., 1998). Alternatively, the competition between hosts and their pathogens offers clear opportunities for selection to play a prominent evolutionary role. Thus, many pathogens show antigenic surface variations as an adaptation mechanism to evade the immune system and successfully colonize host tissues (Parmley et al., 1994; Renia et al., 1997). Nucleotide sequence analysis and serological characterization of outer-membrane proteins (OMPs) may provide insights into the substructure of a homogeneous lineage (based on nucleotide sequence analysis of housekeeping genes) and may identify different subpopulations with an epidemiological interest.
The aim of the present work was to characterize the surface antigens, lipopolysaccharide (LPS) and OMPs of V. vulnificus biotype 3 and to analyse the sequence diversity of selected OMP-encoding genes.
Bacterial isolates and culture media.The study collection consisted of 41 isolates of V. vulnificus, representing all three biotypes: biotype 1 (n=18), biotype 2 (n=4) and biotype 3 (n=19). The list of isolates and their sources is shown in Table 1. Strains were routinely cultured in Trypticasein Soy Agar (TSA) or Broth (TSB) (Pronadisa) supplemented with 0.5 % (w/v) NaCl (TSA-1 or TSB-1) at 25 °C (biotype 2) or 37 °C (biotypes 1 and 3) for 24 h. For the analysis of the OMPs, cells were grown in Marine Sea Water Yeast Extract (MSWYE) (Oliver & Colwell, 1973) for 24 h. MSWYE is a medium that provides cells enough iron-restriction conditions to express iron-regulated OMPs (Esteve-Gassent & Amaro, 2004). Strains were stored in Marine Broth (Difco) plus 20 % (v/v) glycerol at 80 °C.
Table 1. Characteristics of the V. vulnificus isolates used in the study
Antisera.
Anti-biotype 1, 2 and 3 rabbit sera were prepared by intravenous injection of New Zealand rabbits with formalin-killed cells from selected strains (ATCC 27562, biotype 1; CECT 4604, biotype 2, serovar E; and VV12, biotype 3) (see Tables 1 and 4) according to the procedure described by Sorensen & Larsen (1986). One week after the last injection, the rabbits were bled from the ear vein. All sera were stored in aliquots and frozen at 80 °C until used.
Table 4. Titres of antisera raised against selected strains of V. vulnificus biotypes 1, 2 and 3 obtained by dot-blot and agglutinationassays The serovars are indicated in parentheses. T, type strain of the species. Dot-blot titre for each antiserum and antigen combination is expressed as the reciprocal of the highest dilution of serum giving a response above the negative control. Agglutination titre for each antiserum and antigen combination is expressed as the reciprocal of the highest dilution of serum giving a positive agglutination.
Serological testing
Slide-agglutination assay.
The slide-agglutination assay was performed by mixing 20 µl of a cell suspension in sterile saline solution (SS, 0.9 % NaCl, pH 7.4) (109 c.f.u. ml1) with 20 µl of serial twofold dilutions of anti-biotype 1, 2 and 3 serum (Amaro et al., 1992b). The agglutination assay was performed using fresh (thermolabile antigens) and boiled (at 100 °C for 2 h; thermostable antigens) cell suspensions. A distinct and immediate agglutination was defined as positive. Agglutination titre was recorded as the reciprocal of the highest serum dilution giving a positive reaction.
Dot-blot assay.
Dot-blot analysis was performed using thermolabile and thermostable antigens as previously described (Cipriano et al., 1985). Briefly, 1 µl volumes of antigens were dotted onto cellulose membranes (0.5 µm; Bio-Rad) and blocked for 1 h with 3 % (w/v) skimmed milk in Tris-buffered saline (TBS) (50 mM Tris/HCl, pH 7.4). After washing twice with TBS supplemented with 0.05 % Tween 20 (TBS-T), membranes were incubated for 1 h with serial dilutions from 1 : 1000 to 1 : 64 000 of anti-biotype 1, 2 and 3 sera in TBS containing 1 % gelatin (TBS-1). After washing again, membranes were incubated with goat anti-rabbit immunoglobulin G conjugated with alkaline phosphatase (Bio-Rad) diluted at 1 : 3000 in TBS-1 for 1 h. Specific antigenantibody binding was detected by colour development with the substrate solution. Escherichia coli JB101 was used as a negative control. Serum titre was calculated for each antigen as the reciprocal of the lowest antibody dilution giving a similar response to that of the negative control.
Outer-membrane antigens.
OMP and LPS samples were obtained from 24 h bacterial cultures in MSWYE medium as previously described (Amaro et al., 1992a; Biosca et al., 1993). Briefly, at mid-exponential phase the bacterial cells were harvested and disrupted by exposing to distilled water. The cell envelopes were collected by centrifugation at 30 000 g for 30 min and treated with a solution of Sarkosyl (sodium lauroyl sarcosinate) at 0.55 % (w/v) for 10 min. After centrifugation at 18 000 g for 2 h (Biosca et al., 1993), pellets were resuspended in distilled water. Protein concentration was measured by the Lowry method and adjusted to 1 mg ml1. Samples were mixed (1 : 1) with 2x electrophoresis final sample buffer (FSB) (Laemmli, 1970), boiled for 5 min and stored at 20 °C. LPS extractions were prepared from whole-cell lysates according to the method of Hitchcock & Brown (1983) as modified by Amaro et al. (1992a). After proteinase K treatment (Boehringer Mannheim), samples were mixed (1 : 1) with 2x FSB and boiled for 5 min.
SDS-PAGE and immunoblotting.
LPS and OMP samples were analysed by SDS-PAGE (Laemmli, 1970) and immunoblotting according to previously described methods (Amaro et al., 1992a; Biosca et al., 1993; Esteve-Gassent & Amaro, 2004). OMPs were visualized by both Coomassie brilliant blue staining and immunostaining with anti-OmpU or anti-VuuA sera (Esteve-Gassent & Amaro, 2004), and LPS bands by immunostaining with anti-biotype serum (Amaro et al., 1992a). Prior to immunostaining, protein and LPS bands were transferred from the polyacrylamide gels to nitrocellulose sheets (0.45 µm; Bio-Rad) as described by Towbin et al. (1979). Blotting was done at 200 mA for 2 h in Tris/glycine/methanol transfer buffer (25 mM Tris, 192 mM glycine, pH 8.3, and 20 % methanol). The immunological staining of LPS and OMPs was performed using a 1 : 1000 dilution of rabbit anti-biotype 1, 2 and 3 sera, or a 1 : 4000 dilution of anti-OmpU/VuuA serum, respectively (Amaro et al., 1992a; Esteve-Gassent & Amaro, 2004). Pre-stained molecular mass markers (Kaleidoscope Prestained Standards; Bio-Rad) were used as controls.
DNA extraction.
The DNeasy kit (Qiagen) was used to extract DNA with the Gram-negative bacterial protocol as recommended by the manufacturer.
Genes chosen for analysis.
The following OMP-encoding genes were chosen for further analysis: wza, encoding an outer-membrane lipoprotein involved in surface assembly of capsular antigen (Wright et al., 2001); ompU, encoding a major OMP (Park et al., 2006); vuuA, encoding the ferric vulnibactin outer-membrane receptor (Webster & Litwin, 2000); and wcvI, encoding a glycosyltransferase involved in capsule synthesis (Smith & Siebeling, 2003). Mutations in any of these selected genes have been related to some reduction of virulence of vibrios (Provenzano et al., 2001; Smith & Siebeling, 2003; Webster & Litwin, 2000; Wright et al., 2001).
The fragments sequenced from each of these genes are shown in Table 2. Primers were designed based on conserved regions from alignment of the nucleotide sequence of these genes from the two clinical strains of V. vulnificus, CMCP6 (GenBank accession nos AE016795 and AE016796) and YJ016 (GenBank accession nos BA000037 and BA000038) (Chen et al., 2003). The PCR and sequencing primers are shown in Table 3. For the wza and wcvI genes, the same primers were used for PCR amplification and sequencing (in different concentrations: for PCR amplification 100 pmol µl1 and for sequencing 1 pmol µl1). For the ompU and vuuA genes, two sets of sequencing primers were used to sequence the desired size of the gene fragment. The PCR amplification, PCR product precipitation, sequencing reaction and sequencing precipitation methods were carried out as previously described for the MLST studies of V. vulnificus (Bisharat et al., 2005). The sequences were assembled using the Staden suite of computer programs (Staden, 1996). The number of polymorphic nucleotide sites and the calculation of dN/dS ratio (non-synonymous/synonymous substitutions) were estimated using the program START (Jolley et al., 2001). The phylogenetic relationships between the different strains were investigated using distance matrix methods, also known as clustering algorithmic methods [neighbour-joining (NJ) tree], as implemented in MEGA (molecular evolutionary genetic analysis) () version 3.1 (Kumar et al., 2004). The phylogenetic relationships between the different strains based on sequencing of OMP-encoding genes (current study) were compared with the phylogenetic relationships based on concatenated sequences from MLST data from a previous study (Bisharat et al., 2005). For this analysis the nucleotide sequences of 10 MLST loci, making up the sequence type of each strain, were concatenated into a single (4326 bp) length of DNA representing each strain. The bootstrapping method was used to test the accuracy of the clustering. The values on the NJ tree are percentages of 500 computer-generated trees produced by randomly sampling the sequences and are shown at the nodes.
Table 2. Amplicon size and sequenced fragment of the chosen genes
Table 3. Primers used for PCR amplification and sequencing
Serological characterizationAll biotype 3 strains (six strains used for this part of the study), regardless of the antigen used, agglutinated with the antiserum obtained against the selected biotype 3 strain (agglutination titres between 64 and 128) (Table 4). Conversely, they did not agglutinate (titres <2) with antisera against the selected biotype 1 and biotype 2-serovar E strains (Table 4). Likewise, biotype 1 (ATCC 27562) and biotype 2-serovar E (CECT 4604) strains only agglutinated with the homologous antisera (titres between 64 and 128) (Table 4). As expected, the biotype 2 strain of non-serovar E did not agglutinate with anti-CECT 4604 (serovar E) serum (Table 4).
The results of dot-blot assays using thermostable (boiled cells) and thermolabile (fresh cells) antigens from strains of the three biotypes are also shown in Table 4. Titres for each serum, evaluated with the homologous strain, were 64 000, regardless of the antigen used. The anti-biotype 3 serum gave the same titres with all biotype 3 strains, including the homologous strain (Table 4). Clear cross-reactions between biotypes were detected when thermolabile antigens were used (titres between 16 000 and 32 000) but not with thermostable antigens (titres=2000) (Table 4).
OMP patterns from selected strains of the three biotypes are shown in Fig. 1. The OMP patterns of biotype 3 strains were almost identical and similar to those of the selected strains of biotype 1 and 2 (Fig. 1a). Part of the similarity was revealed by immunoblotting with specific antisera (Fig. 1b). Thus, a band that co-migrated as the protein OmpU and the other as protein VuuA were identified in the OMP samples from all strains and biotypes (Fig. 1b). The band patterns of the three biotypes mainly differed in two major bands additional to OmpU, one of about 44 kDa, present in biotype 2 strain (lanes 1 and 2 in Fig. 1a) and the other of about 32 kDa, present in biotype 1 strain (lane 3 in Fig. 1a).
|
LPS of biotype 3 strains was visualized by immunostaining with anti-VV12 serum. All LPS samples from biotype 3 strains exhibited a ladder-like structure typical of smooth LPS (Fig. 2a). The pattern corresponding to O-antigen was clearly different from that exhibited by biotype 1 and 2 strains (Fig. 2b). Three fractions, of high, medium and low mobility, were present in the biotype 3 pattern whereas only one, of medium and of very low mobility, was present in those of biotypes 1 and 2, respectively (Fig. 2b). Finally, LPS samples from biotype 3 strains were not stained with the antisera against the selected strains of biotypes 1 and 2 (Fig. 2b). Conversely, LPS samples from selected biotype 1 and 2 isolates were stained only with their homologous antisera but not with the anti-biotype 3 serum (Fig. 2b).
|
Estimation of sequence diversity
The proportion of the variable nucleotides present in the gene fragments (for all 19 strains used) ranged from 6.4 % (wza) to 56.4 % (ompU) (Table 2). The proportion of nucleotide substitutions that changed the amino acid sequence (non-synonymous substitutions, dN) and the proportion of silent changes (synonymous substitutions, dS) were calculated for each fragment. Using these data, the dN/dS ratios were all above 1 (Table 2), suggesting that there is a selection for a change in amino acid and consistent with the concept that OMP-encoding genes are not under a neutral selection process.
Nucleotide sequence analysis revealed that all biotype 3 strains had identical sequences at each of the four genes examined. This result was in contrast to those of biotypes 1 and 2, for which almost every strain exhibited sequence diversity compared to the other strains of the homologous biotype. Cluster analysis of the individual genes produced two groups, yet the strains within the groups varied by gene (Fig. 3). It also showed that biotype 3 strains form a distinct and homogeneous clone, yet closely related to strains of biotypes 1 and 2, compatible with the OMP patterns obtained using SDS-PAGE (Fig. 1). For presentation purposes, only a subset of the strains was used for constructing the phylogenetic trees (11 biotype 1, 2 biotype 2 and 2 biotype 3 strains). For the wcvI gene only nine sequences are shown; the remaining sequences were identical to the main group in the middle and for presentation purposes were taken out.
|
Correlation with analysis from MLST loci
Analysis of sequence data from these sites (OMP-encoding genes) showed little correlation with the analysis from MLST loci. Closely related strains (based on MLST analysis) did not exhibit similar genetic relatedness when OMP-encoding genes were analysed (Fig. 3). The only exception was biotype 3, which showed a distinct pattern of sequence homogeneity among both MLST loci and OMP-encoding genes. Nevertheless, the phylogenetic analysis using MLST data placed biotype 3 in an intermediate position between the two main populations of V. vulnificus (Fig. 4), whereas the analysis of OMP-encoding genes grouped biotype 3 with one of the two main clusters (Fig. 3).
|
Analysis of DNA sequence diversity of selected OMP-encoding genes showed that biotype 3 strains form a genetically homogeneous clone, yet closely related to those of biotypes 1 and 2. These findings are compatible with the OMP patterns obtained (Fig. 1), suggesting that OMPs from the three biotypes are closely related. In fact, our goal of identifying subpopulations within the homogeneous biotype 3 was not achieved.
Elements suggestive of recent evolution from the parent population of V. vulnificus were associated with biotype 3: the lack of any genetic diversity among both housekeeping genes (Bisharat et al., 2005) and OMP-encoding genes (present analysis), the distinct biochemical characteristics (Bisharat et al., 1999) and the clear association with disease in humans. In fact, biotype 3 and biotype 2-serovar E share some interesting similarities, most remarkably the finding that they both express a homogeneous LPS (Biosca et al., 1996 and present analysis), both are genetically homogeneous among MLST loci (Bisharat et al., 2005, Fig. 4 and unpublished data), both exhibit a distinct biochemical pattern (Bisharat et al., 1999; Tison et al., 1982) and, finally, each has a very specific niche, biotype 2-serovar E primarily affecting eels and biotype 3 affecting only humans.
Maynard Smith et al. (Smith et al., 1993) have suggested a model where clonal lineages emerge due to the acquisition of a strong selective advantage, which allows them to rise rapidly in frequency in the population, and as the strains diverge and specialize on their respective hosts, they become more reproductively isolated, eventually creating distinct lineages. In synthesizing these observations, we hypothesize that biotype 2-serovar E and biotype 3 have only recently descended from the parent population of V. vulnificus.
To date, the homogeneous biotype 3 has been isolated only in Israel. Data suggest that it has been circulating within Israeli fish farms at least since 1981 (Bisharat et al., 1999). Therefore, the exact cause for the disease outbreak in the 1990s has yet to be determined. Initially, it was suggested that changes in fish marketing procedures may have facilitated the disease outbreak (Bisharat & Raz, 1996). However, and despite the implementation of a new fish marketing policy, disease continued (N. Bisharat, unpublished data). A possible link between regional impact of global warming on the Eastern Mediterranean basin and disease outbreak has recently been suggested (Paz et al., 2006).
In view of the trend of exporting stocks of cultured Tilapia fish (from Israel) the appearance of this virulent V. vulnificus biotype in other parts of the world should be considered. Interestingly, it has been speculated that the appearance of biotype 2 in European eel farms has probably occurred due to imports of carrier eels from Japan (Amaro et al., 2001), where the biotype was originally described (Tison et al., 1982).
The distinctiveness of the LPS of biotype 3 from the LPS of the other biotypes of V. vulnificus could be utilized for the development of rapid methods for the specific detection of this pathogen, as has been achieved for biotype 2 (Biosca et al., 1997), and for the generation of LPS-based vaccines. The use of LPS-based vaccines in humans has not been successful so far, because of either the heterogeneity of the LPS molecule or the lack of sufficient immunogenicity, although recently some promising results were reported using immunogenic protein carrier covalently linked to O-deacylated lipopolysaccharide (LPS) derived from Neisseria meningitidis in animal models (Cox et al., 2005). Thus far, the use of LPS-based vaccines against vibriosis in eels has not been promising and the authors suggested that LPS from V. vulnificus serovar E may not be immunogenic for eels (Collado et al., 2000). Others, however, have reported more encouraging results against other vibrios (Fukuda & Kusuda, 1985; Salati & Kusuda, 1985). Studies are currently under way to determine whether the LPS molecule of V. vulnificus biotype 3 can elicit a significant immune response in humans (N. Bisharat, unpublished data).
In summary, the present work reaffirms the highly clonal nature of V. vulnificus biotype 3 and suggests that it has only recently evolved from the parent population. Future studies should focus on utilizing the present data for developing rapid detection methods, inquiring whether the LPS molecule is immunogenic in humans, and determining the feasibility and the effectiveness of LPS-based vaccines in humans.
This work was supported in part by the Wellcome Trust, grant no. 067147/Z/02/Z, and by the Spanish project AGL2005-04688 from the Spanish Ministry for Education and Science (SMES). B. Fouz thanks SMES for her research contract Ramón y Cajal.Edited by: P. H. Everest
Footnotes
†Present address: Department of Medicine, section D, Ha'Emek Medical Center, Afula 18101, Israel.References
Amaro, C., Biosca, E. G., Esteve, C., Fouz, B. & Toranzo, A. E. (1992b). Comparative study of phenotypic and virulence properties in Vibrio vulnficus biotype 1 and 2 obtained from a European eel farm experiencing mortalities. Dis Aquat Organ 13, 2935.
Amaro, C., Fouz, B., Collado, R., Esteve-Gassent, D., Marcelo-Noales, E., Esteve, C., Barrera, R. & Alcaide, E. (2001). Design and development of a vaccine against eel vibriosis caused by Vibrio vulnificus serovar E (or biotype 2) applied to intensive culture facilities (Report). Valencia: Departamento de Microbiologia y Ecologia, Universidad de Valencia, Valencia, Spain.
Biosca, E. G., Garay, E., Toranzo, A. E. & Amaro, C. (1993). Comparison of outer membrane protein profiles of Vibrio vulnificus biotypes 1 and 2. FEMS Microbiol Lett 107, 217222.[CrossRef][Medline]
Biosca, E. G., Oliver, J. D. & Amaro, C. (1996). Phenotypic characterization of Vibrio vulnificus biotype 2, a lipopolysaccharide-based homogeneous O serogroup within Vibrio vulnificus. Appl Environ Microbiol 62, 918927.[Abstract]
Biosca, E. G., Marco-Noales, E., Amaro, C. & Alcaide, E. (1997). An enzyme-linked immunosorbent assay for detection of Vibrio vulnificus biotype 2: development and field studies. Appl Environ Microbiol 63, 537542.[Abstract]
Bisharat, N. & Raz, R. (1996). Vibrio infection in Israel due to changes in fish marketing. Lancet 348, 15851586.[Medline]
Bisharat, N., Agmon, V., Finkelstein, R., Raz, R., Ben-Dror, G., Lerner, L., Soboh, S., Colodner, R., Cameron, D. N. & other authors (1999). Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel. Israel Vibrio Study Group. Lancet 354, 14211424.[CrossRef][Medline]
Bisharat, N., Cohen, D. I., Harding, R. M., Falush, D., Crook, D. W., Peto, T. & Maiden, M. C. (2005). Hybrid Vibrio vulnificus. Emerg Infect Dis 11, 3035.[Medline]
Blake, P. A., Merson, M. H., Weaver, R. E., Hollis, D. G. & Heublein, P. C. (1979). Disease caused by a marine Vibrio. Clinical characteristics and epidemiology. N Engl J Med 300, 15.[Abstract]
Chen, C. Y., Wu, K. M., Chang, Y. C., Chang, C. H., Tsai, H. C., Liao, T. L., Liu, Y. M., Chen, H. J., Shen, A. B. & other authors (2003). Comparative genome analysis of Vibrio vulnificus, a marine pathogen. Genome Res 13, 25772587.
Cipriano, R. C., Pyle, J. B., Starliper, C. E. & Pyle, S. W. (1985). Detection of Vibrio anguillarum antigen by the dot blot assay. J Wildl Dis 21, 211218.[Abstract]
Collado, R., Fouz, B., Sanjuan, E. & Amaro, C. (2000). Effectiveness of different vaccine formulations against vibriosis caused by Vibrio vulnificus serovar E (biotype 2) in European eels Anguilla anguilla. Dis Aquat Organ 43, 91101.[Medline]
Cox, A., Zou, W., Gidney, M. A., Lacelle, S., Plested, J. S., Makepeace, K., Wright, J. C., Coull, P. A., Moxon, E. R. & Richards, J. C. (2005). Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits. Vaccine 23, 50455054.[CrossRef][Medline]
Dalsgaard, A., Frimodt-Moller, N., Bruun, B., Hoi, L. & Larsen, J. L. (1996). Clinical manifestations and molecular epidemiology of Vibrio vulnificus infections in Denmark. Eur J Clin Microbiol Infect Dis 15, 227232.[CrossRef][Medline]
Esteve-Gassent, M. D. & Amaro, C. (2004). Immunogenic antigens of the eel pathogen Vibrio vulnificus serovar E. Fish Shellfish Immunol 17, 277291.[CrossRef][Medline]
Fukuda, Y. & Kusuda, R. (1985). Vaccination of Yellowtail against pseudotuberculosis. Fish Pathol 20, 421425.
Gutacker, M., Conza, N., Benagli, C., Pedroli, A., Bernasconi, M. V., Permin, L., Aznar, R. & Piffaretti, J. C. (2003). Population genetics of Vibrio vulnificus: identification of two divisions and a distinct eel-pathogenic clone. Appl Environ Microbiol 69, 32033212.
Hitchcock, P. J. & Brown, T. M. (1983). Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J Bacteriol 154, 269277.
Jolley, K. A., Feil, E. J., Chan, M. S. & Maiden, M. C. (2001). Sequence type analysis and recombinational tests (START). Bioinformatics 17, 12301231.
Kumar, S., Tamura, K. & Nei, M. (2004). MEGA3: integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 5, 150163.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680685.[CrossRef][Medline]
Maiden, M. C., Bygraves, J. A., Feil, E., Morelli, G., Russell, J. E., Unwin, R., Zhang, Q., Zhou, J., Zurth, K. & other authors (1998). Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95, 31403145.
Oliver, J. D. (1989). Foodborne Bacterial Pathogens, pp. 569600. Edited by M. P. Doyle. New York: Marcel Dekker.
Oliver, J. D. & Colwell, R. R. (1973). Extractable lipids of gram-negative marine bacteria: phospholipid composition. J Bacteriol 114, 897908.
Park, D. K., Lee, K. E., Baek, C. H., Kim, I. H., Kwon, J. H., Lee, W. K., Lee, K. H., Kim, B. S., Choi, S. H. & Kim, K. S. (2006). Cyclo(Phe-Pro) modulates the expression of ompU in Vibrio spp. J Bacteriol 188, 22142221.
Parmley, S. F., Gross, U., Sucharczuk, A., Windeck, T., Sgarlato, G. D. & Remington, J. S. (1994). Two alleles of the gene encoding surface antigen P22 in 25 strains of Toxoplasma gondii. J Parasitol 80, 293301.[CrossRef][Medline]
Paz, S., Bisharat, N., Paz, E., Kidar, O. & Cohen, D. (2006). Climate change and the emergence of Vibrio vulnificus disease in Israel. Environ Res (in press) .
Provenzano, D., Lauriano, C. M. & Klose, K. E. (2001). Characterization of the role of the ToxR-modulated outer membrane porins OmpU and OmpT in Vibrio cholerae virulence. J Bacteriol 183, 36523662.
Renia, L., Ling, I. T., Marussig, M., Miltgen, F., Holder, A. A. & Mazier, D. (1997). Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge. Infect Immun 65, 44194423.[Abstract]
Salati, F. & Kusuda, R. (1985). Vaccine preparations used for immunization of eel Anguilla japonica against Edwarsiella tarda infection. Bull Jpn Soc Sci Fish 51, 12331237.
Smith, A. B. & Siebeling, R. J. (2003). Identification of genetic loci required for capsular expression in Vibrio vulnificus. Infect Immun 71, 10911097.
Smith, J. M., Smith, N. H., O'Rourke, M. & Spratt, B. G. (1993). How clonal are bacteria? Proc Natl Acad Sci U S A 90, 43844388.
Sorensen, U. B. & Larsen, J. L. (1986). Serotyping of Vibrio anguillarum. Appl Environ Microbiol 51, 593597.
Staden, R. (1996). The Staden sequence analysis package. Mol Biotechnol 5, 233241.[Medline]
Tison, D. L., Nishibuchi, M., Greenwood, J. D. & Seidler, R. J. (1982). Vibrio vulnificus biogroup 2: new biogroup pathogenic for eels. Appl Environ Microbiol 44, 640646.
Towbin, H., Staehelin, T. & Gordon, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76, 43504354.
Webster, A. C. & Litwin, C. M. (2000). Cloning and characterization of vuuA, a gene encoding the Vibrio vulnificus ferric vulnibactin receptor. Infect Immun 68, 526534.
Wright, A. C., Powell, J. L., Kaper, J. B. & Morris, J. G., Jr (2001). Identification of a group 1-like capsular polysaccharide operon for Vibrio vulnificus. Infect Immun 69, 68936901.
Received 26 October 2006; revised 26 November 2006; accepted 6 December 2006.